- Japan
- /
- Medical Equipment
- /
- TSE:7741
Analysts Have Made A Financial Statement On HOYA Corporation's (TSE:7741) Half-Yearly Report
HOYA Corporation (TSE:7741) just released its latest half-yearly results and things are looking bullish. The company beat expectations with revenues of JP¥428b arriving 4.6% ahead of forecasts. Statutory earnings per share (EPS) were JP¥287, 4.5% ahead of estimates. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.
See our latest analysis for HOYA
After the latest results, the 15 analysts covering HOYA are now predicting revenues of JP¥862.6b in 2025. If met, this would reflect a credible 6.1% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to accumulate 4.7% to JP¥590. Yet prior to the latest earnings, the analysts had been anticipated revenues of JP¥860.1b and earnings per share (EPS) of JP¥595 in 2025. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.
There were no changes to revenue or earnings estimates or the price target of JP¥22,600, suggesting that the company has met expectations in its recent result. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. Currently, the most bullish analyst values HOYA at JP¥26,000 per share, while the most bearish prices it at JP¥19,200. Analysts definitely have varying views on the business, but the spread of estimates is not wide enough in our view to suggest that extreme outcomes could await HOYA shareholders.
Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. It's clear from the latest estimates that HOYA's rate of growth is expected to accelerate meaningfully, with the forecast 13% annualised revenue growth to the end of 2025 noticeably faster than its historical growth of 8.4% p.a. over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 6.5% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that HOYA is expected to grow much faster than its industry.
The Bottom Line
The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have forecasts for HOYA going out to 2027, and you can see them free on our platform here.
We also provide an overview of the HOYA Board and CEO remuneration and length of tenure at the company, and whether insiders have been buying the stock, here.
Valuation is complex, but we're here to simplify it.
Discover if HOYA might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSE:7741
HOYA
A med-tech company, provides high-tech and medical products worldwide.
Outstanding track record with flawless balance sheet.